ATXS vs. APLT, CDMO, ABUS, CMPS, AVTE, LRMR, AVBP, VERV, ALT, and KALV
Should you be buying Astria Therapeutics stock or one of its competitors? The main competitors of Astria Therapeutics include Applied Therapeutics (APLT), Avid Bioservices (CDMO), Arbutus Biopharma (ABUS), COMPASS Pathways (CMPS), Aerovate Therapeutics (AVTE), Larimar Therapeutics (LRMR), ArriVent BioPharma (AVBP), Verve Therapeutics (VERV), Altimmune (ALT), and KalVista Pharmaceuticals (KALV). These companies are all part of the "pharmaceutical preparations" industry.
Astria Therapeutics (NASDAQ:ATXS) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment, risk and community ranking.
Astria Therapeutics' return on equity of -53.14% beat Applied Therapeutics' return on equity.
In the previous week, Astria Therapeutics had 9 more articles in the media than Applied Therapeutics. MarketBeat recorded 18 mentions for Astria Therapeutics and 9 mentions for Applied Therapeutics. Astria Therapeutics' average media sentiment score of 0.47 beat Applied Therapeutics' score of 0.17 indicating that Astria Therapeutics is being referred to more favorably in the media.
Astria Therapeutics received 484 more outperform votes than Applied Therapeutics when rated by MarketBeat users. Likewise, 72.55% of users gave Astria Therapeutics an outperform vote while only 56.35% of users gave Applied Therapeutics an outperform vote.
Astria Therapeutics presently has a consensus price target of $22.50, suggesting a potential upside of 134.38%. Applied Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 142.29%. Given Applied Therapeutics' higher possible upside, analysts plainly believe Applied Therapeutics is more favorable than Astria Therapeutics.
Astria Therapeutics has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, Applied Therapeutics has a beta of 1.91, indicating that its stock price is 91% more volatile than the S&P 500.
Astria Therapeutics has higher earnings, but lower revenue than Applied Therapeutics. Astria Therapeutics is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.
99.0% of Astria Therapeutics shares are held by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are held by institutional investors. 2.9% of Astria Therapeutics shares are held by insiders. Comparatively, 8.6% of Applied Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Astria Therapeutics beats Applied Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Astria Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATXS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Astria Therapeutics Competitors List
Related Companies and Tools
